- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 61177-44-4] Clavulanatelithium
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-A0256B |
| Brand: | MCE |
| CAS: | 61177-44-4 |
Overview
| MDL | MFCD22666231 |
|---|---|
| Molecular Weight | 205.09 |
| Molecular Formula | C8H8LiNO5 |
| SMILES | O=C([C@@H](/C(O[C@]1([H])C2)=C/CO)N1C2=O)O[Li] |
3 Publications Citing Use of MCE
Summary
Clavulanate lithium is a potent β-lactamase inhibitor and acts as an antibiotic [1] [2] .
IC50 & Target
β-lactamase [1]
In Vitro
Clavulanate lithium has weak antibacterial activity against most organisms when administered alone, but given in combination with beta-lactam antibiotics prevents antibiotic inactivation by microbial lactamase
[1]
.
Clavulanate lithium (0.25, 0.5 mg/L) causes a relatively slow inhibition of growth, and a higher concentration (1 mg/L) is only marginally more effective than 0.5 mg/L
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | L. pneumophila NCTC 1119 |
| Concentration: | 0.25 mg/L, 0.5 mg/L, 1 mg/L |
| Incubation Time: | 0-35 hours |
| Result: | Caused a relatively slow inhibition of growth. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04411914 | Temple University|Beth Israel Deaconess Medical Center|University of Pennsylvania Perelman School of Medicine |
Cocaine Dependence
|
September 1, 2020 | Phase 1 |
| NCT03986762 | Temple University|National Institute on Drug Abuse (NIDA) |
Cocaine Dependence, in Remission|Cocaine Abuse, in Remission|Cocaine-Related Disorders
|
March 12, 2019 | Phase 1 |
| NCT02007603 | Medical University of Vienna |
Infection During Hemodialysis
|
August 2013 | Phase 3 |
| NCT01096927 | Maggiore Bellaria Hospital, Bologna |
Lower Abdominal Pain|Right Iliac Fossa Pain|Acute Appendicitis
|
January 2010 | Phase 4 |
| NCT00917592 | Consorci Sanitari de Terrassa|Corporacion Parc Tauli |
Diverticulitis
|
December 2005 | Phase 4 |
| NCT04400110 | IRCCS Burlo Garofolo |
Urinary Tract Infections
|
June 8, 2020 | Phase 4 |
| NCT05079620 | UConn Health |
Aspiration|Aspiration Pneumonia
|
November 30, 2021 | Phase 4 |
| NCT01015417 | Centre Hospitalier Universitaire, Amiens |
Acute Lithiasic Cholecystitis Grade I or II|Symptoms Lasting for Less Than 5 Days|Required Cholecystectomy|Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days
|
May 2010 | Phase 3 |
| NCT00495586 | Catalan Society of Family Medicine|Fondo de Investigacion Sanitaria |
Chronic Obstructive Pulmonary Disease
|
October 2007 | Phase 4 |
| NCT02571959 | Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba |
Obesity
|
July 24, 2015 | Phase 1|Phase 2 |
| NCT05562349 | Temple University|University of Pennsylvania Perelman School of Medicine|Medical University of South Carolina|Research Foundation for Mental Hygiene, Inc. |
Cocaine Dependence
|
October 2022 | Phase 2 |
| NCT02563769 | Temple University|National Institute on Drug Abuse (NIDA)|University of Pennsylvania |
Cocaine Dependence|Cocaine Addiction|Cocaine Abuse|Cocaine-Related Disorders
|
September 2016 | Phase 1 |
| NCT02186951 | University Hospital, Limoges |
Ventilator-associated Pneumonia|Cardiac Arrests With Shockable Rhythm|Mild Therapeutic Hypothermia|Preventive Antibiotics
|
August 18, 2014 | Phase 3 |
| NCT03809312 | CHU de Quebec-Universite Laval |
Chronic Sinus Infection
|
August 14, 2019 | Phase 4 |
| NCT04980170 | Jordan University Hospital |
Antibiotics Causing Adverse Effects in Therapeutic Use
|
November 1, 2021 | Early Phase 1 |
| NCT00656747 | Bayer |
Chronic Bronchitis
|
March 2008 | Phase 4 |
| NCT00665873 | Universita degli Studi di Catania |
Infections
|
January 2004 | Phase 4 |
| NCT04350502 | Centre Hospitalier Universitaire, Amiens |
Pleural Infection|Empyema|Community-acquired Pneumonia|Pharmacokinetic|Amoxicillin
|
April 4, 2020 | Not Applicable |
| NCT03713424 | University of Missouri-Columbia |
Tobacco Use Disorder
|
March 26, 2019 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 33.33 mg/mL ( 162.51 mM ; Need ultrasonic)
DMSO : 4.17 mg/mL ( 20.33 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.8759 mL | 24.3795 mL | 48.7591 mL |
| 5 mM | 0.9752 mL | 4.8759 mL | 9.7518 mL |
| 10 mM | 0.4876 mL | 2.4380 mL | 4.8759 mL |
References
- [1] Reading C, et al. Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977 May; 11(5): 852–857.
- [2] Stokes DH, et al. Bactericidal effects of amoxycillin/clavulanic acid against intracellular Legionella pneumophila in tissue culture studies. J Antimicrob Chemother. 1989 Apr;23(4):547-56.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.